|
US5457208A
(en)
|
1993-06-21 |
1995-10-10 |
Regents Of The University Of Minnesota |
Kappa opioid receptor antagonists
|
|
TR200103237T2
(tr)
|
1999-05-12 |
2002-04-22 |
F. Hoffmann-La Roche Ag |
İmidazodiazepin türevi
|
|
US20020052365A1
(en)
|
2000-10-05 |
2002-05-02 |
Mohler Hanns |
Selective anxiolytic therapeutic agents
|
|
JP2004518654A
(ja)
|
2000-12-21 |
2004-06-24 |
ザ マクレーン ホスピタル コーポレーション |
鬱病の治療法
|
|
US6974824B2
(en)
|
2001-01-08 |
2005-12-13 |
Research Triangle Institute |
Kappa opioid receptor ligands
|
|
DE60319812T2
(de)
|
2002-03-28 |
2009-04-23 |
Wisys Technology Foundation, Inc., Madison |
Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
|
|
KR101025633B1
(ko)
|
2002-09-19 |
2011-03-30 |
일라이 릴리 앤드 캄파니 |
오피오이드 수용체 안타고니스트로서의 디아릴 에테르
|
|
ATE406360T1
(de)
|
2003-03-07 |
2008-09-15 |
Lilly Co Eli |
Antagonisten der opioidrezeptoren
|
|
EP1613597B1
(en)
|
2003-03-07 |
2007-11-07 |
Eli Lilly and Company |
6-substituted nicotinamide derivatives as opioid receptor antagonists
|
|
CA2549009A1
(en)
|
2003-12-12 |
2005-07-07 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
ES2390459T3
(es)
|
2003-12-22 |
2012-11-13 |
Eli Lilly And Company |
Antagonistas de receptores de opioides
|
|
DE602005022572D1
(de)
|
2004-03-12 |
2010-09-09 |
Lilly Co Eli |
Antagonisten des opioidrezeptors
|
|
EP1729759A4
(en)
|
2004-03-12 |
2008-04-02 |
Mclean Hospital Corp |
SALVINORINE DERIVATIVES AND ITS USES
|
|
ATE399164T1
(de)
|
2004-03-12 |
2008-07-15 |
Lilly Co Eli |
Antagonisten des opioidrezeptors
|
|
DE602005012380D1
(de)
|
2004-03-15 |
2009-03-05 |
Lilly Co Eli |
4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
|
|
EP1735268B1
(en)
|
2004-03-15 |
2012-02-15 |
Eli Lilly And Company |
Opioid receptor antagonists
|
|
WO2007067714A2
(en)
|
2005-12-08 |
2007-06-14 |
The Mclean Hospital Corporation |
Treatment of sequelae of psychiatric disorders
|
|
JP5128578B2
(ja)
|
2006-04-04 |
2013-01-23 |
エモディス ゲーエムベーハー |
解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用
|
|
EP2049481A2
(en)
|
2006-08-09 |
2009-04-22 |
SmithKline Beecham Corporation |
Novel compounds as antagonists or inverse agonists for opioid receptors
|
|
EP2054383A2
(en)
|
2006-08-09 |
2009-05-06 |
SmithKline Beecham Corporation |
Novel compounds as antagonists or inverse agonists at opioid receptors
|
|
KR20090051778A
(ko)
|
2006-09-08 |
2009-05-22 |
화이자 프로덕츠 인코포레이티드 |
다이아릴 에터 유도체 및 이의 용도
|
|
JP5345637B2
(ja)
|
2008-01-22 |
2013-11-20 |
イーライ リリー アンド カンパニー |
κ選択的オピオイド受容体アンタゴニスト
|
|
WO2012016569A1
(en)
|
2010-08-05 |
2012-02-09 |
Conrig Pharma Aps |
Deuterated tandospirone derivatives as 5-ht1a receptor agonists
|
|
ES2631607T3
(es)
|
2011-12-09 |
2017-09-01 |
Research Triangle Institute, International |
4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa
|
|
ES2694352T3
(es)
|
2013-12-20 |
2018-12-20 |
H. Lundbeck A/S |
Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
|
|
WO2016156396A1
(en)
|
2015-03-30 |
2016-10-06 |
University Of Innsbruck |
Diphenethylamine derivatives which are inter alia useful as analgesics and methods for their production
|
|
US10709685B2
(en)
|
2015-05-28 |
2020-07-14 |
Georgetown University |
Use of methadone metabolites for treatment of anxiety and depression
|
|
EP3468540A4
(en)
|
2016-06-13 |
2020-03-18 |
Board Of Regents Of the University Of Texas System |
PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
|
|
US20190240293A1
(en)
|
2016-07-26 |
2019-08-08 |
Flagship Pioneering Innovations V, Inc. |
Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
|
|
US11292783B2
(en)
|
2016-09-16 |
2022-04-05 |
Research Triangle Institute |
Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists
|
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
|
AU2018234931B2
(en)
|
2017-03-17 |
2022-05-26 |
Blackthorn Therapeutics, Inc. |
Kappa opioid receptor antagonists and products and methods related thereto
|
|
PH12018000077B1
(en)
|
2017-07-05 |
2021-07-09 |
Frimline Private Ltd |
A pharmaceutical composition for neuropathic pain
|
|
US20190255036A1
(en)
|
2018-02-16 |
2019-08-22 |
Alexander Kariman |
Compound and method for reducing neuropathic pain and depression
|
|
JP7416751B2
(ja)
|
2018-03-23 |
2024-01-17 |
ユニバーシティ オブ カンザス |
環状テトラペプチド類似体
|
|
US11491144B2
(en)
|
2018-03-30 |
2022-11-08 |
The Florida State University Research Foundation, Incorporated |
Methods of treating fragile X mental retardation syndrome
|
|
EP3870030A4
(en)
|
2018-10-23 |
2022-08-03 |
Blackthorn Therapeutics, Inc. |
SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS
|
|
US20200171025A1
(en)
|
2018-11-29 |
2020-06-04 |
Srinivasa Rao Parella |
Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
|
|
US11266627B1
(en)
*
|
2021-05-04 |
2022-03-08 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for the treatment of depression
|
|
CN114195693A
(zh)
*
|
2020-09-17 |
2022-03-18 |
广东东阳光药业有限公司 |
一种酰胺化合物的晶型及其制备方法
|
|
PH12023552963A1
(en)
*
|
2021-05-04 |
2024-03-11 |
Janssen Pharmaceuticals Inc |
Compositions and methods for the treatment of depression
|
|
US12161622B2
(en)
|
2021-05-04 |
2024-12-10 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for the treatment of depression
|
|
AU2023231493A1
(en)
|
2022-03-07 |
2024-10-24 |
Janssen Pharmaceuticals, Inc. |
Pure forms of crystalline aticaprant
|
|
WO2023170554A1
(en)
|
2022-03-07 |
2023-09-14 |
Janssen Pharmaceuticals, Inc. |
Compositions comprising aticaprant
|